Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II maintenance sintilimab in PD-L1-positive extensive-stage small cell lung cancer
ChiCTR1800018861Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in small cell lung cancer (SCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Started Oct 2018; status: recruiting.
02
Drugs
sintilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR1800018861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018861.